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Abstract
There is considerable evidence that hearing and vestibular function can be influenced by immune processes. The inner ear has evolved
mechanisms, such as the blood–labyrinthine barrier that limit immune responses and autoimmune processes to reduce the potential for
damage to cochlear cells. Recently, expression of Fas ligand (FasL) in some non-lymphoid tissue, as in the anterior chamber of the eye, has
been hypothesized to play a role in protection of sensitive organs from activated T-cells. We show that under resting conditions, cochlear cells
express little or no FasL. However, after exposure to interferon-g in vitro, FasL is induced in many neonatal cochlear cells. In addition, we
show that FasL is upregulated in adult cochlear cells after induction of a sterile labyrinthitis in vivo. The induction of FasL by inflammation
may serve to limit cochlear immune responses, and to protect sensorineural tissue from immune and autoimmune damage.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The FasL–Fas cell-to-cell signaling system plays a
crucial role in a variety of biological processes, including
development and tissue homeostasis, through the induction
of programmed cell death. This system also plays a specific
role in immune cytotoxicity, immune cell homeostasis and
autoimmunity (Siegel et al., 2000). FasL is a trimeric type II
membrane protein of approximately 37 kDa and belongs to
the TNF superfamily (Suda and Nagata, 1994; Suda et al.,
1993; Takahashi et al., 1994). Its receptor, Fas is a 319-
amino acid type I transmembrane glycoprotein with an 80-
amino acid region, the death domain, that serves as a
module for protein–protein interaction and is critical for
apoptosis signaling (Itoh et al., 1991; Tartaglia et al., 1993).
When FasL binds to Fas on target cells, caspases are
activated and the cells die by programmed cell death
(Nagata and Golstein, 1995; Suda et al., 1995).
The Fas death receptor is expressed by many cell types,
including most lymphocytes and inflammatory cells. How-
ever, as one would expect, expression of FasL is tightly
regulated. FasL is expressed strongly on activated T-cells
and NK cells, where it participates in killing of infected or
neoplastic cells, and in the deletion of autoreactive T-cells
(Suda et al., 1995; Bossi and Griffiths, 1999). However,
recently a growing number of non-lymphoid cells have been
shown to express FasL. For example, cells in the anterior
chamber of the eye (Griffith et al., 1995) and Sertoli cells of
the testis (Bellgrau et al., 1995) constitutively express FasL.
The FasL–Fas system plays an essential role in the eye, as
mice which express a nonfunctional Fas receptor display
ocular inflammation with inflammatory infiltrates in the
choroid and sclera (Jabs and Prendergast, 1991; Jabs et
al., 1996). Constitutive FasL expression has been suggested
to be involved in protection of immune-privileged sites from
immune-mediated damage (Griffith et al., 1995; Griffith et
al., 1996; Green and Ferguson, 2001).
There is considerable evidence that hearing and vestib-
ular function can be influenced by immune and autoimmune
processes (Ma et al., 2000; Rahman et al., 2001; Ryan et al.,
2001). Although the immune system can protect the inner
ear, immune-related inflammatory responses can also be
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deleterious, resulting in degeneration of cochlear cells. The
inner ear appears to have evolved mechanisms, such as the
blood–labyrinthine barrier, which limit immune responses
and minimize autoimmunity, in order to prevent damage to
the sensitive sensory cells and neurons. Mice deficient in
Fas exhibit hearing loss that has been attributed to auto-
immune processes (Trune et al., 1989; Ruckenstein et al.,
1999). Therefore, it is possible, that FasL participates in the
regulation of immunity in the inner ear. The purpose of the
present study was to determine whether FasL is expressed in
normal cochlear cells and whether there is an upregulation
of FasL during cochlear inflammation.
2. Materials and methods
2.1. Animals and dissection
All procedures were approved by an animal subject
committee (VA Medical Center, La Jolla, CA, USA) in
accordance with the NIH guidelines regarding experimental
procedures. Postnatal days 3–5 CBA mice were sacrificed
and dissected as described previously (Van de Water and
Ruben, 1971; Aletsee et al., 2001). Briefly, after anaesthe-
sia, the skull was opened midsagitally under sterile con-
ditions, and the temporal bone identified after removal of
the brain. Employing a dissection microscope, the membra-
nous labyrinth was exposed after gentle removal of the bony
and cartilaginous cochlear capsule. The lateral wall tissue,
the organ of Corti, the spiral ganglion, and the modiolus
including the vasculature and the distal portion of the VIII
nerve were microdissected.
2.2. Cell culture
Each of the tissue samples was immediately trans-
ferred into the well of a 48-well tissue culture plate
(Costar) in Dulbecco’s phoshate-buffered saline (Gibco).
Four explants were pooled per well. In order to obtain a
single cell suspension, explants were digested with 1 mg/
ml trypsin, 10 mg/ml collagenase, and 1 mg/ml elastase
(Sigma, St. Louis, USA) for 40 min at 37 jC. After
removal of the supernatant, 500 Al PBS containing 5%
fetal calf serum (FCS), Hepes buffer 0.025 M, and
penicillin 30 U/ml was added per well. Cell dispersion
was accomplished by trituration using a 1-cm3 syringe.
Spleen tissue served as a control and was treated iden-
tically. Each respective cell population was split into two.
One aliquot was stimulated with 100 IU/ml recombinant
mouse interferon-g (R&D Systems, USA) for 24 h,
which was repeated for a total of 48 h of interferon
stimulation. The other aliquot remained unstimulated.
Interferon-g was employed to stimulate the inner ear
cells in culture, because this cytokine is an early mediator
of inflammation and has been shown to be a potent
inducer of FasL in several cellular systems (Choi et al.,
1999). For the time course study, the cells were harvested
after 6, 12, 24, and 48 h of interferon stimulation (for 6–
24 h, n = 1; for 48 h, n = 5). All tissues were cultured at
37 jC and 5% CO2.
2.3. Fluorescent staining and flow cytometric analysis
(FACS)
After final removal of the supernatant, incubation with
a purified rat IgG anti-mouse CD16/CD32 monoclonal
antibody was performed for 10 min at 4 jC (2 Al/well)
to block nonspecific adherence of antibodies to mouse
Fc receptors (Fc Block, Pharmingen). Cells were then
washed and incubated for 30 min at 37 jC with a
polyclonal goat anti-mouse FasL antibody (1:100, Santa
Cruz Biotechnology, USA). The cells were washed twice
with PBS and incubated for 45 min at 4 jC with a rabbit
anti-goat IgG FITC-conjugated antibody (1:100, Jackson
Immuno, USA). Cells were washed twice with cold PBS,
gently detached with 400 Al accutase (Cell Technology,
San Diego, CA, USA) and gently removed from the
wells. Flow cytometric acquisition of the samples was
performed on a FACScan (Becton Dickinson, San Jose,
CA) using a standard Cell Quest acquisition/analysis
software. Five thousand live events, which were gated
on their forward/side scatter characteristics, were col-
lected. Unstimulated spleen cells were used as a negative
control for nonspecific binding of the secondary antibody.
The primary antibody was replaced by the same volume
of PBS and the threshold was adjusted so that less than
1% of the cells were gated. This threshold was then used
for all samples. As an additional control, each inner ear
cell population was individually stimulated and unstimu-
lated with interferon-g for 48 h and analyzed using the
secondary antibody only.
2.4. Induction of sterile labyrinthitis in mice
This procedure has been described in detail in a
previous publication (Takahashi and Harris, 1988).
Briefly, mice were immunized subcutaneously with the
antigen keyhole limpet hemocyanin (KLH), (Pacific Bio-
marine Supply, Venice, CA) in complete Freunds adju-
vant and boosted 10 days later with KLH in incomplete
Freunds adjuvant. For the inner ear challenge, the right
middle ear bulla was opened and the posterior half of the
tympanic membrane removed. A microhole was drilled
into the basal turn of the cochlea and 5 Al KLH injected
slowly into the cochlea. The hole was sealed with bone
wax. Seven days after the inner ear challenge, the
animals were deeply anaesthetized and perfused with
intracardiac perfusion with periodate–lysin–paraformalde-
hyde fixative. After removal and decalcification of the
temporal bones with 4% EDTA at 4 jC, the tissue was
frozen in OCT compound (Tissue Tec, Naperville, IL,
USA).
D. Bodmer et al. / Journal of Neuroimmunology 129 (2002) 10–17 11
Fig. 1. Spleen, lateral wall, organ of Corti, modiolus, and spiral ganglion were harvested and dissociated, and half of the cells were treated with interferon-g for
48 h. Both populations were then subjected to FACS analysis to measure FasL expression. A representative run is shown. The green line in a denotes sorting of
spleen cells without the FasL antibody, as a negative control. The red and blue lines represent sorting of untreated or interferon-g-treated cells, respectively,
using both the primary and secondary antibodies. The green and black line in f denote sorting of untreated or interferon-g-treated cells, respectively, using the
secondary antibody only. No primary ab = no primary antibody.
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2.5. Immunohistochemistry
The frozen temporal bone was serially sectioned (5–7
Am) in the direction of the modiolus. After air-drying of the
sections, an indirect immunoperoxidase technique was used
with a primary polyclonal goat anti-mouse FasL antibody
(1:75 to 1:200, Santa Cruz Biotechnology) incubated for 1 h
at room temperature. Further staining was carried out
employing a secondary rabbit anti-goat IgG antibody
(1:2000, Vectastain ABC kit, Vector Laboratories, Burlin-
game, CA, USA) and the color reaction was performed with
DAB (Vector Laboratories). A slight counterstaining with
hematoxylin was performed at the end. For negative control,
the primary antibody was replaced by PBS or goat serum.




The number of inner ear cells ranged from 8000 to
12000 per well. The survival rate was about 65–75% after
48 h in culture, as shown by trypan blue exclusion, irres-
pective of the population and interferon-g stimulation.
3.2. FACS results with and without interferon-g stimulation
FasL was expressed in unstimulated spleen cultures, in a
resting state, at a value of 1% with an increase to 75% after
interferon-g treatment (Fig. 1a). On resting inner ear cells,
the ligand was expressed at levels ranging from 3% to 8%
(Fig. 1b–e). After stimulation with interferon-g, FasL was
Fig. 2. (a) Represents the average of five independent runs of FACS after 48 h interferon-g stimulation, as illustrated in Fig. 1. Statistical analysis was
performed using the Mann–Whitney U-test. Bars represent mean values, standard errors are indicated by lines. SPL Ø=negative control (unstimulated spleen
without FasL antibody), SPL= unstimulated spleen, SPL+ = stimulated spleen, LW= unstimulated lateral wall, LW+= stimulated lateral wall,
OC = unstimulated organ of Corti, OC+ = stimulated organ of Corti, MOD = unstimulated modiolus, MOD+= stimulated modiolus, SG = unstimulated
ated spiral ganglion, SG+= stimulated spiral ganglion ( * p< 0.01; in each group, the unstimulated value was compared to the stimulated value). (b) Represents
a time course study with FACS runs after 0, 6, 12, 24, and 48 h of interferon-g stimulation, as illustrated in Fig. 1. Each bar represents one FACS run.
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upregulated 48 h later to values from 35% to 53% (Figs.
1b–e and 2a). In the control experiment, sorting of unsti-
mulated and stimulated inner ear cells without the primary
antibody resulted in lower than 2% positivity for all inner
ear portions, as an example, the result for sorting of cells
from the modiolus is shown (Fig. 1f). In the time course
study, we observed an increase of FasL expression over
time, with the maximal expression at 24 h after the initial
stimulation with interferon-g in spleen, lateral wall, organ of
Corti, and modiolus. Maximal expression was observed 48
h after the initial stimulation with interferon-g in spiral
ganglion (Fig. 2b).
3.3. FasL expression during labyrinthitis
Normal spleen tissue displayed strong immunoreactivity
for FasL in the interfollicular region (Fig. 3a). Except for a
faint staining of the spiral ganglion, no FasL immunoreac-
Fig. 3. Immunohistochemical localization of FasL molecules in normal spleen (a), normal inner ear (b), and inner ear during labyrinthitis (c– f). (a) Normal
spleen, arrows indicate FasL-positive cells (brown) in the interfollicular region. LF = lymphoid follicle. (b) Normal cochlea demonstrating only background
FasL labeling. OC= organ of Corti, RM=Reissner membrane, SL= spiral limbus, SM= scala media, ST= scala tympani, SV= scala vestibuli, TM= tectorial
membrane. (c) Strongly FasL-positive inflammatory cells (arrows) in the scala tympani 7 days after induction of labyrinthitis. (d) Moderately FasL-positive
supporting cells (arrow) of the crista ampullaris in labyrinthitis. (e) Moderately FasL-positive marginal cells (arrow) of the stria vascularis in labyrinthitis. (f)
Moderately FasL-positive spiral ganglion neurons (arrows) in labyrinthitis.
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tivity was detected in the untreated inner ear (Fig. 3b). One
week after induction of a sterile labyrinthitis, the treated
inner ear showed a strong FasL immunoreactivity inf 20%
of the infiltrating leukocytes (Fig. 3c). Supporting cells of
the crista ampullaris, marginal cells of the stria vascularis
and neurons of the spiral ganglion showed moderate FasL
immunostaining in the treated inner (Fig. 3d–f), whereas the
organ of Corti displayed a weak FasL immunostaining in
supporting cells (data not shown). When the primary anti-
body was replaced with PBS or goat serum, background
staining was very low in all sections (data not shown).
4. Discussion
FACS is an established method in experimental biology
in a variety of fields, including brain and immunology
research (Weller et al., 1996; Brehm et al., 1999; Herzen-
berg and De Rosa, 2000). However, its application to the
study of the inner ear is new. This technique offers advan-
tages, such as preservation of antigenicity in unfixed tissue
and reproducible stimulation of cells in culture. Disadvan-
tages of FACS include trauma associated with the dissoci-
ation process, changes in cellular characteristics due to
culture conditions, and heterogeneity of cell populations.
For these reasons, we compared our FACS findings to
immunohistochemical data using an established model of
inner ear inflammation in the adult mouse (Harris and Ryan,
1984).
When dispersed neonatal cochlear cells from lateral wall,
organ of Corti, modiolus and spiral ganglion were stimu-
lated with repeated doses of interferon-g, a significant
increase of FasL was detected using FACS, in contrast to
untreated control cells. In immune-mediated labyrinthitis,
FasL was detected in infiltrating inflammatory cells and in
subpopulations of cochlear cells such as spiral ganglion
neurons, supporting cells in sensory epithelia, and marginal
cells of the stria vascularis. Agreement of the results
obtained with the two methods is therefore good, but it
was not complete. For example, we saw little FasL immu-
nolabeling in modiolar tissue sections, but FACS analysis of
interferon-g-treated modiolar samples showed many cells
that were positive for FasL. This may be related to differ-
ences in the nature of the two methods. The FACS data were
obtained during 6–48 h of inflammatory stimulation with a
single cytokine, while the histochemical analysis was
obtained after 1 week of naturally mediated inflammation.
In any event, the data from both methods support the
expression of FasL by the inflamed inner ear.
The expression of FasL in the inner ear implies a func-
tional role for FasL–Fas signaling. Recently, it has been
shown that treatment of cultured cochlear sensory cells with
cisplatin results in increased expression of Fas receptor (Van
de Water et al., 2001). In addition, the MRL-Faslpr/lpr mouse,
which expresses a nonfunctional Fas receptor, displays
progressive hearing loss not seen in the background MRL
strain. This may be related to autoimmunity since this
mouse shows progressive accumulation of autoreactive T-
lymphocytes. However, the most striking inner ear pathol-
ogy of the Fas mutant mouse is found in the stria vascularis,
with progressive hydrops and degeneration of strial cells in
the absence of leukocyte infiltration of the stria (Trune et al.,
1989; Ruckenstein et al., 1999). These data provide evi-
dence that the Fas–FasL system plays a role in the inner ear,
but the nature of this role remains obscure.
The central nervous system (CNS), and the inner ear by
extension, were originally thought to be immunoprivileged
sites through the actions of the blood–brain and blood–
labyrinthine barriers, respectively. However, this view has
been altered by many observations. With respect to the inner
ear, systemic immunity has been shown to protect the
cochlea from subsequent viral labyrinthitis (Woolf et al.,
1985). Antigens introduced into the cochlea of a naı¨ve
animal produce a brisk systemic immune response (Harris,
1983; Harris et al., 1985), while introduction of antigens
into the inner ear of systemically immunized animals results
in hearing loss due to a vigourous secondary immune
response (Woolf and Harris, 1986; Ma et al., 2000). The
concept that autoimmunity might damage the labyrinth
resulting in bilateral, progressive sensorineural hearing loss
(SNHL) was introduced in McCabe (1979). Autoimmunity
has since been proposed as an etiology for Meniere’s disease
(Hughes et al., 1988), sudden SNHL (Moskowitz et al.,
1984), and acute vertigo (Hughes et al., 1985). These and
other data provide evidence that immune mechanisms and
their associated inflammatory response can cause damage to
sensitive auditory and/or vestibulary cells.
While the inner ear does not appear to be immunoprivi-
leged, the blood–labyrinthine barrier does exclude lympho-
cytes and most immunoglobulins from the normal cochlea.
The inner ear may have evolved additional mechanisms by
which to limit immune damage. In the corneal epithelium,
iris, and ciliary cells of the eye, as well as in Sertoli cells of
the testis, FasL is constitutively expressed (Bellgrau et al.,
1995; Griffith et al., 1995). It has been proposed that
activated lymphocytes that enter these sites are killed by
the FasL expressed on these cells (Griffith et al., 1996;
Bellgrau et al., 1995). However, in contrast to the eye and
the testis, we find little or no constitutive expression of FasL
in the inner ear. Only upon stimulation with interferon-g or
after the induction of labyrinthitis did we observe FasL
expression on subpopulations of cochlear cells such as spiral
ganglion neurons, supporting cells in sensory epithelia, and
marginal cells of the stria vascularis. This is consistent with
the idea that the inner ear is not an immunologically
privileged site. Rather, the inner ear seems to display
restricted immunity unless provoked. It is possible that the
upregulation of FasL limits immune responses in the inner
ear, and so protects the tissues of the labyrinth from the later
stages of immune-mediated damage. The advantages of
active immunity may outweigh the advantages of immune
privilege in the inner ear, until inflammation is strongly
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activated. If this interpretation is correct, it is possible that
application of FasL might protect the inner ear from
immune-mediated damage.
A striking feature of the results is the fact that all of the
cell populations tested by FACS analysis showed increases
in FasL. This may reflect the fact that many of the cells of
the cochlea are exposed to cochlear fluids, and thus are
vulnerable to damage from leukocytes that are typically
observed in cochlear fluids during inflammation. It should
also be noted that each population tested consisted of
several different inner ear cell types. Thus, there were a
number of potential candidates for FasL expression in each.
Indeed, the FACS data indicated that only about 40% of the
cells in each population were positive for FasL immunor-
eactivity. Similarly, the histochemical data indicated that
only subsets of the cells in different regions of the cochlea
were labeled with anti-FasL antibodies.
The specific cell types labeled in the cytochemical study
may reflect potential cellular targets of FasL and/or the
cochlear cells meant to be protected by FasL expression.
Production of FasL by infiltrating leukocytes may target
other inflammatory cells, in order to limit inflammatory
damage to the inner ear. Expression by supporting cells in
inner ear sensory epithelia may be designed to protect the
delicate sensory cells. It can be argued that the receptor cells
themselves are so specialized that they may be unable to
express FasL. In the stria vascularis, the marginal cells may
be protecting themselves and underlying cells from inflam-
matory cells in the endolymph, since they directly face this
fluid compartment.
While FasL expression was seen in many inner ear cells
types, the time course of expression observed by FACS
differed between cell populations of different origins. The
most rapid response was observed in the modiolar samples,
for which FasL positivity reached maximal levels in 12 h,
while the slowest response was seen in the spiral ganglion,
which did not peak until 48 h. The rapid modiolar response
may occur because this is the normal site of leukocyte entry
into the inner ear. The spiral modiolar vein has been shown
to be the most active site of inner ear leukocyte recruitment
during inflammation (Harris et al., 1990). Cells in the
modiolus may thus be programmed to respond more rapidly
to inflammatory stimuli. The delayed response seen in the
spiral ganglion may reflect the fact that spiral ganglion
neuron cell bodies are completely sheated in myelin. The
cytochemical results indicated that the neurons expressed
FasL, not the glial cells or fibroblasts of the ganglion.
Access of interferon-g to the neurons may have been
impeded by shielding effects of myelin, thus delaying the
response.
It should be noted that FasL expression in the inflamed
inner ear may have functions unrelated to protection from
immune and inflammatory cells. For example, it has
recently been demonstrated that FasL inhibits angiogenesis
beneath the retina (Kaplan et al., 1999). The formation of
new blood vessels could be deleterious for the inner ear and,
in fact, angiogenesis is not generally observed in inflamed
cochleas. The induced expression of FasL could help to
limit neovascularization that might otherwise be stimulated
by inflammatory mediators.
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